EE686 Cost Effectiveness of Ruxolitinib for Treatment of Steroid Refractory Acute Graft Versus Host Disease in Patients >12 Years of Age from a Singapore Healthcare System Perspective

Authors
Category Primary study
JournalValue in health
Year 2023
This article has no abstract
Epistemonikos ID: 6e3ef793445f4547dcd482d1cfb154f003fe836c
First added on: Apr 29, 2024